Trial Profile
Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Anaplastic astrocytoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- Acronyms GEINO
- 06 Oct 2020 Results published in the Targeted Oncology
- 04 Feb 2020 Planned End Date changed from 1 Dec 2018 to 1 Mar 2020.
- 04 Jun 2019 Status changed from recruiting to discontinued as the trial was stopped early due to lack of efficacy, according to the results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.